BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 208 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,373 | -33.2% | 11,917 | -33.6% | 0.00% | – |
| Q2 2023 | $126,262 | -0.7% | 17,935 | +17.6% | 0.00% | – |
| Q1 2023 | $127,160 | -9.4% | 15,247 | +24.8% | 0.00% | – |
| Q4 2022 | $140,286 | +15.0% | 12,220 | +26.0% | 0.00% | – |
| Q3 2022 | $122,000 | +139.2% | 9,700 | +102.8% | 0.00% | – |
| Q2 2022 | $51,000 | -13.6% | 4,783 | +30.3% | 0.00% | – |
| Q1 2022 | $59,000 | -16.9% | 3,672 | -29.1% | 0.00% | – |
| Q4 2021 | $71,000 | +7000.0% | 5,178 | +5718.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 89 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 89 | -13.6% | 0.00% | – |
| Q4 2017 | $1,000 | 0.0% | 103 | -65.8% | 0.00% | – |
| Q2 2016 | $1,000 | 0.0% | 301 | -3.8% | 0.00% | – |
| Q1 2016 | $1,000 | 0.0% | 313 | +172.2% | 0.00% | – |
| Q4 2015 | $1,000 | – | 115 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
| Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
| Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
| Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
| DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
| KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
| Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
| ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
| Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |